Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 ...

Shares of Novavax Inc. NVAX slid 2.86% to $12.56 Wednesday, on what proved to be an all-around dismal trading session for the ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

The Food and Drug Administration (FDA) has authorized the emergency use of the Novavax COVID-19 Vaccine, Adjuvanted.

Health Canada said Thursday it has authorized Novavax's updated COVID-19 vaccine for those aged 12 years and up.

Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $12.78 which represents a slight increase of $1.15 or 9.89% from the prior close of $11.63. The stock opened at $11.76 and touched a low ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Epidemiologists and a federal health agency have criticized new COVID-19 guidance from Florida Surgeon General Joseph Ladapo ...

After hitting a two-year high in June on enthusiasm for its updated Covid vaccine, shares have pulled back. Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its ...